Sherry Aulin's Insider Trades & SAST Disclosures
Sherry Aulin's most recent trade in Xenon Pharmaceuticals Inc was a trade of 16,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Dec. 18, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Sherry Aulin.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Xenon Pharmaceuticals Inc | Sherry Aulin | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2024 | 16,000 | 6,000 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Aulin Sherry | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.58 per share. | 18 Dec 2024 | 16,000 | 16,000 (0%) | 0% | 11.6 | 185,280 | Common Shares |
| Xenon Pharmaceuticals Inc | Aulin Sherry | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 41.19 per share. | 18 Dec 2024 | 11,510 | 0 (0%) | 0% | 41.2 | 474,097 | Common Shares |
| Xenon Pharmaceuticals Inc | Sherry Aulin | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.44 per share. | 18 Dec 2024 | 9,334 | 9,334 (0%) | 0% | 9.4 | 88,113 | Common Shares |
| Xenon Pharmaceuticals Inc | Aulin Sherry | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2024 | 9,334 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Aulin Sherry | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 41.23 per share. | 18 Dec 2024 | 7,199 | 0 (0%) | 0% | 41.2 | 296,815 | Common Shares |
| Xenon Pharmaceuticals Inc | Aulin Sherry | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.28 per share. | 18 Dec 2024 | 4,490 | 11,510 (0%) | 0% | 41.3 | 185,347 | Common Shares |
| Xenon Pharmaceuticals Inc | Sherry Aulin | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.28 per share. | 18 Dec 2024 | 2,135 | 7,199 (0%) | 0% | 41.3 | 88,133 | Common Shares |
| Xenon Pharmaceuticals Inc | Sherry Aulin | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2024 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Sherry Aulin | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2023 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Sherry Aulin | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 39.57 per share. | 02 Sep 2022 | 15,355 | 0 (0%) | 0% | 39.6 | 607,597 | Common Shares |
| Xenon Pharmaceuticals Inc | Sherry Aulin | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.44 per share. | 02 Sep 2022 | 9,000 | 9,000 (0%) | 0% | 9.4 | 84,960 | Common Shares |
| Xenon Pharmaceuticals Inc | Sherry Aulin | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2022 | 9,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Sherry Aulin | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.75 per share. | 02 Sep 2022 | 6,511 | 18,648 (0%) | 0% | 4.7 | 30,927 | Common Shares |
| Xenon Pharmaceuticals Inc | Sherry Aulin | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2022 | 6,511 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Sherry Aulin | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.53 per share. | 02 Sep 2022 | 3,293 | 15,355 (0%) | 0% | 39.5 | 130,172 | Common Shares |
| Xenon Pharmaceuticals Inc | Sherry Aulin | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.10 per share. | 02 Sep 2022 | 2,292 | 12,137 (0%) | 0% | 3.1 | 7,105 | Common Shares |
| Xenon Pharmaceuticals Inc | Sherry Aulin | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2022 | 2,292 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Sherry Aulin | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.40 per share. | 02 Sep 2022 | 813 | 9,845 (0%) | 0% | 8.4 | 6,829 | Common Shares |
| Xenon Pharmaceuticals Inc | Sherry Aulin | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2022 | 813 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Sherry Aulin | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.50 per share. | 02 Sep 2022 | 32 | 9,032 (0%) | 0% | 7.5 | 240 | Common Shares |
| Xenon Pharmaceuticals Inc | Sherry Aulin | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2022 | 32 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Sherry Aulin | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Sherry Aulin | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges